Recent 8-K filings for RAPP
Highest-materiality recent filing
Rapport Therapeutics closes private placement of 1,058,824 shares at $17.00 per share with existing stockholders
- Entered Stock Purchase Agreements with Sofinnova Venture Partners and affiliates of Goldman Sachs for 1,058,824 shares at $17.00/share, concurrent with IPO.
- Private placement closed June 10, 2024; placement agents included Goldman Sachs, Jefferies, TD Securities, and Stifel.
-
Rapport's RAP-219 hits Phase 2 primary endpoint in bipolar mania (3.1-pt YMRS gain, p=0.045)
Phase 2 met primary endpoint: 3.1-point placebo-adjusted YMRS improvement at Week 3 (p=0.045); 15.4-point mean reduction from baseline vs 12.3 on placebo.
-
Rapport Therapeutics Q2 net loss $56.6M; initiates RAP-219 Phase 3 in focal seizures
Net loss $56.6M in Q2 2026 vs $26.7M in Q2 2025; R&D spend $51.4M (up from $22.7M).
-
Rapport Therapeutics stockholders elect three Class II directors and ratify PwC as auditor
James Healy, M.D., Ph.D. elected with 41,762,713 for, 587,163 withheld; broker non-votes 1,983,035.
-
Rapport Q1 net loss $19.9M, cash $476.8M; RAP-219 Phase 3 in FOS on track for Q2 2026
Net loss $19.9M (vs $24.1M YoY); collaboration revenue $20.0M from Tenacia deal.
-
RAP-219 Phase 2a follow-up shows sustained seizure reduction; half-life updated to ~22 days
90% median reduction in clinical seizures in weeks 9-12; 59% in weeks 13-16, demonstrating sustained effect after treatment cessation.
-
Rapport Therapeutics reports FY2025 net loss $111.5M, RAP-219 Phase 2 positive, Phase 3 Q2 2026
Net loss Q4 2025 $33.8M, full year $111.5M; R&D expenses $94.8M FY2025 vs $60.9M FY2024.
-
Phase 3 program for RAP-219 in focal onset seizures accelerated to Q2 2026 (from Q3) after FDA End-of-Phase 2 meeting.
-
Rapport Therapeutics registers up to $110M in at-the-market stock offering
Filed prospectus supplement on Jan 7, 2026 to sell up to $110M of common stock through Leerink and Cantor Fitzgerald.
-
Rapport: Phase 2a RAP-219 meets endpoints; 77.8% median seizure reduction; Q3 net loss $26.9M
Phase 2a in drug-resistant focal seizures: 77.8% median clinical seizure reduction, 24% seizure freedom, 85.2% with ≥30% LE reduction (all p<0.01).
-
Rapport Therapeutics announces $234.7M public offering of 9.6M shares at $26.00 per share
Underwriting agreement for 9,615,385 shares at $26.00; underwriters option for up to 1,442,307 additional shares.
-
Rapport RAP-219 Phase 2a positive: 85.2% achieved ≥30% LE reduction, 24% seizure freedom
85.2% of patients achieved ≥30% reduction in long episodes (p<0.0001); median LE reduction 71%.
-
Rapport Therapeutics terminates ATM equity offering program; no shares sold
Effective Sept 8, 2025, terminated the ATM prospectus under the S-3 registration statement.
-
Net loss of $26.7M for Q2 2025 vs $18.1M YoY; R&D expenses $22.7M and G&A $6.8M.
-
Rapport Therapeutics stockholders re-elect three Class I directors and ratify PwC as auditor
Reid Huber, Ph.D., John Maraganore, Ph.D., and Wendy B. Young, Ph.D. elected as Class I directors for terms expiring 2028.
-
RAP-219 Phase 2a fully enrolled; topline data Sept 2025; safety profile clean
Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled; topline results expected September 2025.
-
Rapport Therapeutics Q1 net loss $24.1M; RAP-219 epilepsy trial on track for Q3 2025 data
Net loss $24.1M in Q1 2025 vs $22.7M prior year; R&D expenses rose to $19.6M from $12.5M.
-
Rapport Therapeutics FY2024 net loss $78.3M; RAP-219 epilepsy trial top line Q3 2025
Net loss $78.3M for FY2024 vs $34.8M in FY2023; R&D expense $60.9M up from $28.0M.
-
Rapport hires Dr. Jeffrey Sevigny as CMO; Phase 2a data expected Q3 2025
Jeffrey Sevigny, former CMO at Prevail Therapeutics (Eli Lilly), appointed CMO effective immediately.
-
Rapport reports positive Phase 1 RAP-219 data; CMO steps down
PET trial: dosing regimen used in Phase 2a epilepsy trial exceeded target receptor occupancy (50-70%) within 5 days.
-
Rapport Therapeutics Q3 net loss $17.5M; DPNP IND on clinical hold; cash $320.7M
Net loss $17.5M vs $8.7M prior year; R&D expense $15.5M (up from $7.6M) driven by clinical development.
-
Rapport Therapeutics Q2 net loss $18.1M; cash $336.1M; IPO raised $174.4M gross
Net loss $18.1M vs $6.4M YoY; R&D expense $15.7M vs $4.7M YoY.
-
Entered Stock Purchase Agreements with Sofinnova Venture Partners and affiliates of Goldman Sachs for 1,058,824 shares at $17.00/share, concurrent with IPO.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.68 · Most common event other_material